Determining the Optimal Carbapenem MIC That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae

ABSTRACT Carbapenemase-producing (CP) Enterobacteriaceae are largely responsible for the rapid spread of carbapenem-resistant Enterobacteriaceae (CRE). Distinguishing CP-CRE from non-CP-CRE has important infection control implications. In a cohort of 198 CRE isolates, for isolates that remained susceptible or intermediate to some carbapenem antibiotics, an ertapenem MIC of 0.5 μg/ml and meropenem, imipenem, and doripenem MICs of 2 μg/ml were best able to distinguish CP-CRE from non-CP-CRE isolates.

[1]  J. Patel,et al.  FDA-CDC Antimicrobial Resistance Isolate Bank: a Publicly Available Resource To Support Research, Development, and Regulatory Requirements , 2017, Journal of Clinical Microbiology.

[2]  K. Carroll,et al.  The Prevalence and Molecular Epidemiology of Multidrug-Resistant Enterobacteriaceae Colonization in a Pediatric Intensive Care Unit , 2016, Infection Control & Hospital Epidemiology.

[3]  P. Tamma,et al.  Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE) , 2016, Expert review of anti-infective therapy.

[4]  R. Lynfield,et al.  Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae , 2015, Emerging infectious diseases.

[5]  Samir N. Patel,et al.  Evaluation of the Carba NP Test for Rapid Detection of Carbapenemase-Producing Enterobacteriaceae and Pseudomonas aeruginosa , 2013, Antimicrobial Agents and Chemotherapy.

[6]  P. Nordmann,et al.  Value of the Modified Hodge Test for Detection of Emerging Carbapenemases in Enterobacteriaceae , 2011, Journal of Clinical Microbiology.

[7]  Thierry Naas,et al.  Global Spread of Carbapenemase-producing Enterobacteriaceae , 2011, Emerging infectious diseases.

[8]  D. Livermore,et al.  Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams. , 1997, The Journal of antimicrobial chemotherapy.

[9]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[10]  R. Walker.  Standards for antimicrobial susceptibility testing. , 1999, American journal of veterinary research.